Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma Abstract #48

Introduction: Medullary thyroid carcinoma (MTC) accounts for about 5-10% of all thyroid cancers, and while disease localized to the thyroid can be cured by surgery, there is no effective treatment for disseminated MTC. Constitutive activation of the RET proto-oncogene is implicated in familial and a proportion of sporadic cases, and up-regulates the AKT/PI3-kinase/mTOR signal transduction pathway. Recent studies have shown that the inhibitor of mTOR, everolimus (RAD001, Novartis, Basel), can inhibit the proliferation of the TT cell line and human MTC tumor cells in vitro. Clinically, everolimus has been shown to attenuate the progression of some gastrointestinal neuroendocrine tumors, but its clinical use in MTC has not yet been evaluated.
Aim(s): An early progress report on the use of RAD001 in the clinical treatment of a patient with progressive MTC.
Materials and methods: A patient with metastatic MTC received RAD001 (with institutional approval for compassionate use) and the effects evaluated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maralyn R Druce

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2732 Prostate Metastasis of Medullary Thyroid Carcinoma in a Young Patient with MEN2B Syndrome
Introduction: Multiple Endocrine Neoplasia 2B is associated with particularly early onset medullary thyroid carcinoma (MTC). Metastatic MTC is the leading cause of early death in MEN2B. The usual sites of metastasis are neck, mediastinum, lung, liver, bone and brain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Jane Noble
#2813 Clinical Presentation and Prognosis of Patients with Medullary Thyroid Cancer
Introduction: Medullary thyroid carcinoma (MTC) is a rare type of tumor that originates from parafollicular C-cells and accounts for 3–4% of all malignant thyroid neoplasms. MTC presents as sporadic (75–80%) or inherited tumors (20–25%). Hereditary MTC is part of multiple endocrine neoplasia type 2 (MEN2).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Federica de Cicco
#3074 Medullary Thyroid Carcinoma and DIPNECH: An Unexpected Association
Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour of the C-cells of thyroid gland. Diffuse idiopathic pulmonary neuroendocrine cells hyperplasia (DIPNECH) is a rare condition, thought to be primarily a neuroendocrine proliferative process which can develop into carcinoid tumours.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Joana Lima Ferreira
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#266 Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that everolimus, an mTOR inhibitor, has a potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Chiara Zatelli